These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37864520)

  • 1. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
    Knisely A; Ahmed J; Stephen B; Piha-Paul SA; Karp D; Zarifa A; Fu S; Hong DS; Rodon Ahnert J; Yap TA; Tsimberidou AM; Alshawa A; Dumbrava EE; Yang Y; Song J; Meric-Bernstam F; Jazaeri AA; Naing A
    Cancer; 2024 Feb; 130(3):400-409. PubMed ID: 37864520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
    Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
    Cohen EEW; Pishvaian MJ; Shepard DR; Wang D; Weiss J; Johnson ML; Chung CH; Chen Y; Huang B; Davis CB; Toffalorio F; Thall A; Powell SF
    J Immunother Cancer; 2019 Dec; 7(1):342. PubMed ID: 31801624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
    Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
    Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
    Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
    Tolcher AW; Sznol M; Hu-Lieskovan S; Papadopoulos KP; Patnaik A; Rasco DW; Di Gravio D; Huang B; Gambhire D; Chen Y; Thall AD; Pathan N; Schmidt EV; Chow LQM
    Clin Cancer Res; 2017 Sep; 23(18):5349-5357. PubMed ID: 28634283
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
    Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
    Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lee NY; Ferris RL; Psyrri A; Haddad RI; Tahara M; Bourhis J; Harrington K; Chang PM; Lin JC; Razaq MA; Teixeira MM; Lövey J; Chamois J; Rueda A; Hu C; Dunn LA; Dvorkin MV; De Beukelaer S; Pavlov D; Thurm H; Cohen E
    Lancet Oncol; 2021 Apr; 22(4):450-462. PubMed ID: 33794205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.
    Knisely A; Hinchcliff E; Fellman B; Mosley A; Lito K; Hull S; Westin SN; Sood AK; Schmeler KM; Taylor JS; Huang SY; Sheth RA; Lu KH; Jazaeri AA
    Med; 2024 Apr; 5(4):311-320.e3. PubMed ID: 38471508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
    Friedman CF; Snyder Charen A; Zhou Q; Carducci MA; Buckley De Meritens A; Corr BR; Fu S; Hollmann TJ; Iasonos A; Konner JA; Konstantinopoulos PA; Modesitt SC; Sharon E; Aghajanian C; Zamarin D
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.
    Choi MC; Moon YW; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim G; Kim KA
    Yonsei Med J; 2020 Oct; 61(10):844-850. PubMed ID: 32975058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
    Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
    J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
    Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
    Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
    JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
    du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
    Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
    Hong DS; Gopal AK; Shoushtari AN; Patel SP; He AR; Doi T; Ramalingam SS; Patnaik A; Sandhu S; Chen Y; Davis CB; Fisher TS; Huang B; Fly KD; Ribas A
    Front Immunol; 2022; 13():897991. PubMed ID: 35983060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.